Diazyme announces partnership with Maccura for COVID-19 test, also launches FDA EUA
Diazyme Laboratories has announced a partnership with Maccura Biotechnology (USA) LLC, as well as the launch of its SARS-COV-2 RT-PCR diagnostics test, which has received emergency use authorization (EUA) from the U.S. Food and Drug Administration, according to a release from Diazyme.
“Here at Diazyme, we continue to address gaps in testing during the COVID-19 public health emergency. The SARS-CoV-2 Fluorescent PCR Kit- Maccura Biotechnology (USA) is a RT-PCR test intended for the qualitative detection of SARS-CoV-2 viral nucleic acids in upper respiratory specimens (e.g., oropharyngeal swabs, nasopharyngeal swabs, nasal swabs, and mid-turbinate swabs) from individuals suspected of COVID-19. The demand for molecular diagnostic tests continues to outpace availability and wait times are getting too long to be meaningful in quarantine situations. We are pleased to announce our partnership with Maccura, bringing more test capacity to clinical laboratories", said Chong Yuan, PhD, Managing Director of Diazyme Laboratories.
Jinson Xu, the General Manager of Maccura Biotechnology (USA) LLC, said, “Maccura Biotechnology (USA) is pleased to enter into a partnership with Diazyme Laboratories providing additional testing capacity during the public health emergency in the USA. We have a long business relationship with Diazyme and continue to work together in many areas globally.”
